Alzheimer’s Trials Guidance Feedback Calls for Clarity on Disease Later-Stage Protocols

Alzheimer’s drugmakers including Biogen, Eli Lilly and Eisai, as well as consumer advocacy group Public Citizen, have characterized a recent FDA guidance on developing drugs for Alzheimer’s as lacking in specifics for later-stage disease progression.
Source: Drug Industry Daily